From DSM to ICN
Former DSM Pharmaceuticals CEO Wesley Wheeler is named North American president of ICN Pharmaceuticals. Company notes that Wheeler has experience with "business turnarounds," cites his tenure at DSM. Wheeler joined the contract manufacturing firm as part of a management overhaul following several problematic FDA inspections. Prior to joining DSM, Wheeler was senior VP-logistics & strategy for GlaxoSmithKline (1"The Pink Sheet" Sept. 30, 2002, p. 30)...
You may also be interested in...
DSM Pharmaceuticals is highlighting new environmental monitoring systems in its response to FDA about recent good manufacturing practices inspections
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.
Pfizer has pressed on with the launch of a fourth biosimilar pegfilgrastim product, Nyvepria (pegfilgrastim-apgf), according to an investment bank. With Amgen continuing to hold more than 70% of the market, there is opportunity for Pfizer to capture significant market share.